Long-term Follow-up of Study Participant Treated With Lentiviral-Based Genetically Modified Autologous Cell Product ,AGT103-T

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
American Gene Technologies International Inc.
Study ID
NCT05529342
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Gene modified therapy — BIOLOGICAL
    No investigational cell product will be administered

Study Details

Long-term follow-up of study subjects who received AGT103-T product in HIV study. The AGT103-T is genetically modified cells that resist infection with HIV causing a depletion of HIV in HIV-infected study participants.

Key Dates

Start date
Aug 29, 2022
Status verified
Nov 2022
Primary completion
May 23, 2038
Completion
Sep 29, 2038

Study Design

Enrollment
7 participants (estimated)

Primary Outcome Measure

Assess the incidence of delayed adverse events (AE) to gene therapy [ Time Frame: 1year to 15years post infusion ]

Locations (2)

FacilityCityStateZIPSite coordinators
Georgetown UniversityWashington D.C.District of Columbia20007-
Washington Health InstituteWashington D.C.District of Columbia20017-

Find similar trials in Washington D.C., DC

By condition
HIV
By specialty
Infectious disease
By research site
Georgetown University· Washington D.C., DCWashington Health Institute· Washington D.C., DC

Related Studies